



Pressrelease April 10, 2008

## **GENOVIS: THE NEW SHARE ISSUE WAS OVERSUBSCRIBED**

**Genovis AB (publ) has carried out its earlier published new share issue with preferential rights to existing shareholders. There has been a high interest and the new share issue is fully subscribed.**

98 % of the new share issue was subscribed with preferential rights. The rest of the shares were subscribed without preferential rights within the frame of the highest amount of the issuing. The issuing ensures Genovis approximately 14 MSEK after issue expenses. The number of shares increased from 8,708,987 to 10,886,233.

Contract note and notification of allotment of shares subscribed without subscription rights is estimated to be sent out around the April 14, 2008.

For more information, contact:

Sarah Fredriksson, CEO, Genovis AB

+46-46-10 12 30

[sarah.fredriksson@genovis.com](mailto:sarah.fredriksson@genovis.com)

*Genovis is a biotech company on the leading edge of nanotechnology and nanoparticles. The company's patented nano-induced magnetic transfer (NIMT®) technology was developed to facilitate effective preclinical research for the life science industry. Genovis shares are listed on the First North OMX Nordic Exchange. Mangold Fondkommission is our certified advisor and liquidity guarantor.*